The emergence of GLP-1 receptor agonists, including medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), has revolutionized the treatment of diabetes and obesity. These medications have gained widespread attention for their remarkable effectiveness in promoting weight loss and improving metabolic health. However, as more individuals begin using these treatments, an important question arises: How do GLP-1 medications affect mental health and emotional well-being?